Treatment of graves' disease and associated opthalmopathy with the anti-CD20 monoclonal antibody rituximab: An open study

Mario Salvi, Guia Vannucchi, Irene Campi, Nicola Currò, Davide Dazzi, Simona Simonetta, Paola Bonara, Stefania Rossi, Clara Sina, Claudio Guastella, Roberto Ratiglia, Paola Beck-Peccoz

Research output: Contribution to journalArticle

Abstract

Introduction: Hyperthyroid Graves' disease (GD) is a B-cell-mediated condition caused by TSH receptor antibodies (TRAb), which decline when GD remits. Anti-CD20 monoclonal antibody rituximab (RTX) induces transient B-cell depletion that may potentially modify the active inflammatory phase of thyroid-associated ophthalmopathy (TAO). Methods: Nine patients with GD, (seven with active TAO, two with mild lid signs) were studied. The trial was only approved as an open pilot study; thus we compared the effect of RTX therapy to that of i.v. glucocorticoids (IVGC) in 20 consecutive patients. Patients were treated with RTX (1000 mg i.v. twice at 2-week interval) or with IVGC (500 mg i.v. for 16 weeks). TAO was assessed by the clinical activity score (CAS) and severity was classified using NOSPECS (No signs or symptoms; Only signs (lid); Soft tissue involvement; Proptosis, Extraocular muscle involvement; Corneal involvement: Sight loss). Thyroid function and lymphocyte count were measured by standardized methods. Results: All patients attained peripheral B-cell depletion with the first RTX infusion. Minor side effects were reported in three patients. Thyroid function was not affected by RTX therapy and hyperthyroid patients required therapy with methimazole. After RTX, the changes in the levels of thyroglobulin antibodies, thyroperoxidase antibodies and TRAb were neither significant nor correlated with CD20 + depletion (P = NS). CAS values before RTX were 4.7 ± 0.5 and decreased to 1.8 ± 0.8 at the end of follow-up (P

Original languageEnglish
Pages (from-to)33-40
Number of pages8
JournalEuropean Journal of Endocrinology
Volume156
Issue number1
DOIs
Publication statusPublished - Jan 2007

Fingerprint

Graves Disease
Monoclonal Antibodies
Graves Ophthalmopathy
B-Lymphocytes
Hyperthyroidism
Therapeutics
Glucocorticoids
Oculomotor Muscles
Thyroid Gland
Methimazole
Exophthalmos
Antibodies
Thyroglobulin
Lymphocyte Count
Rituximab
Signs and Symptoms

ASJC Scopus subject areas

  • Endocrinology

Cite this

Treatment of graves' disease and associated opthalmopathy with the anti-CD20 monoclonal antibody rituximab : An open study. / Salvi, Mario; Vannucchi, Guia; Campi, Irene; Currò, Nicola; Dazzi, Davide; Simonetta, Simona; Bonara, Paola; Rossi, Stefania; Sina, Clara; Guastella, Claudio; Ratiglia, Roberto; Beck-Peccoz, Paola.

In: European Journal of Endocrinology, Vol. 156, No. 1, 01.2007, p. 33-40.

Research output: Contribution to journalArticle

Salvi, M, Vannucchi, G, Campi, I, Currò, N, Dazzi, D, Simonetta, S, Bonara, P, Rossi, S, Sina, C, Guastella, C, Ratiglia, R & Beck-Peccoz, P 2007, 'Treatment of graves' disease and associated opthalmopathy with the anti-CD20 monoclonal antibody rituximab: An open study', European Journal of Endocrinology, vol. 156, no. 1, pp. 33-40. https://doi.org/10.1530/eje.1.02325
Salvi, Mario ; Vannucchi, Guia ; Campi, Irene ; Currò, Nicola ; Dazzi, Davide ; Simonetta, Simona ; Bonara, Paola ; Rossi, Stefania ; Sina, Clara ; Guastella, Claudio ; Ratiglia, Roberto ; Beck-Peccoz, Paola. / Treatment of graves' disease and associated opthalmopathy with the anti-CD20 monoclonal antibody rituximab : An open study. In: European Journal of Endocrinology. 2007 ; Vol. 156, No. 1. pp. 33-40.
@article{b8370d09e66e4dda8196243aa13b39b5,
title = "Treatment of graves' disease and associated opthalmopathy with the anti-CD20 monoclonal antibody rituximab: An open study",
abstract = "Introduction: Hyperthyroid Graves' disease (GD) is a B-cell-mediated condition caused by TSH receptor antibodies (TRAb), which decline when GD remits. Anti-CD20 monoclonal antibody rituximab (RTX) induces transient B-cell depletion that may potentially modify the active inflammatory phase of thyroid-associated ophthalmopathy (TAO). Methods: Nine patients with GD, (seven with active TAO, two with mild lid signs) were studied. The trial was only approved as an open pilot study; thus we compared the effect of RTX therapy to that of i.v. glucocorticoids (IVGC) in 20 consecutive patients. Patients were treated with RTX (1000 mg i.v. twice at 2-week interval) or with IVGC (500 mg i.v. for 16 weeks). TAO was assessed by the clinical activity score (CAS) and severity was classified using NOSPECS (No signs or symptoms; Only signs (lid); Soft tissue involvement; Proptosis, Extraocular muscle involvement; Corneal involvement: Sight loss). Thyroid function and lymphocyte count were measured by standardized methods. Results: All patients attained peripheral B-cell depletion with the first RTX infusion. Minor side effects were reported in three patients. Thyroid function was not affected by RTX therapy and hyperthyroid patients required therapy with methimazole. After RTX, the changes in the levels of thyroglobulin antibodies, thyroperoxidase antibodies and TRAb were neither significant nor correlated with CD20 + depletion (P = NS). CAS values before RTX were 4.7 ± 0.5 and decreased to 1.8 ± 0.8 at the end of follow-up (P",
author = "Mario Salvi and Guia Vannucchi and Irene Campi and Nicola Curr{\`o} and Davide Dazzi and Simona Simonetta and Paola Bonara and Stefania Rossi and Clara Sina and Claudio Guastella and Roberto Ratiglia and Paola Beck-Peccoz",
year = "2007",
month = "1",
doi = "10.1530/eje.1.02325",
language = "English",
volume = "156",
pages = "33--40",
journal = "European Journal of Endocrinology",
issn = "0804-4643",
publisher = "BioScientifica Ltd.",
number = "1",

}

TY - JOUR

T1 - Treatment of graves' disease and associated opthalmopathy with the anti-CD20 monoclonal antibody rituximab

T2 - An open study

AU - Salvi, Mario

AU - Vannucchi, Guia

AU - Campi, Irene

AU - Currò, Nicola

AU - Dazzi, Davide

AU - Simonetta, Simona

AU - Bonara, Paola

AU - Rossi, Stefania

AU - Sina, Clara

AU - Guastella, Claudio

AU - Ratiglia, Roberto

AU - Beck-Peccoz, Paola

PY - 2007/1

Y1 - 2007/1

N2 - Introduction: Hyperthyroid Graves' disease (GD) is a B-cell-mediated condition caused by TSH receptor antibodies (TRAb), which decline when GD remits. Anti-CD20 monoclonal antibody rituximab (RTX) induces transient B-cell depletion that may potentially modify the active inflammatory phase of thyroid-associated ophthalmopathy (TAO). Methods: Nine patients with GD, (seven with active TAO, two with mild lid signs) were studied. The trial was only approved as an open pilot study; thus we compared the effect of RTX therapy to that of i.v. glucocorticoids (IVGC) in 20 consecutive patients. Patients were treated with RTX (1000 mg i.v. twice at 2-week interval) or with IVGC (500 mg i.v. for 16 weeks). TAO was assessed by the clinical activity score (CAS) and severity was classified using NOSPECS (No signs or symptoms; Only signs (lid); Soft tissue involvement; Proptosis, Extraocular muscle involvement; Corneal involvement: Sight loss). Thyroid function and lymphocyte count were measured by standardized methods. Results: All patients attained peripheral B-cell depletion with the first RTX infusion. Minor side effects were reported in three patients. Thyroid function was not affected by RTX therapy and hyperthyroid patients required therapy with methimazole. After RTX, the changes in the levels of thyroglobulin antibodies, thyroperoxidase antibodies and TRAb were neither significant nor correlated with CD20 + depletion (P = NS). CAS values before RTX were 4.7 ± 0.5 and decreased to 1.8 ± 0.8 at the end of follow-up (P

AB - Introduction: Hyperthyroid Graves' disease (GD) is a B-cell-mediated condition caused by TSH receptor antibodies (TRAb), which decline when GD remits. Anti-CD20 monoclonal antibody rituximab (RTX) induces transient B-cell depletion that may potentially modify the active inflammatory phase of thyroid-associated ophthalmopathy (TAO). Methods: Nine patients with GD, (seven with active TAO, two with mild lid signs) were studied. The trial was only approved as an open pilot study; thus we compared the effect of RTX therapy to that of i.v. glucocorticoids (IVGC) in 20 consecutive patients. Patients were treated with RTX (1000 mg i.v. twice at 2-week interval) or with IVGC (500 mg i.v. for 16 weeks). TAO was assessed by the clinical activity score (CAS) and severity was classified using NOSPECS (No signs or symptoms; Only signs (lid); Soft tissue involvement; Proptosis, Extraocular muscle involvement; Corneal involvement: Sight loss). Thyroid function and lymphocyte count were measured by standardized methods. Results: All patients attained peripheral B-cell depletion with the first RTX infusion. Minor side effects were reported in three patients. Thyroid function was not affected by RTX therapy and hyperthyroid patients required therapy with methimazole. After RTX, the changes in the levels of thyroglobulin antibodies, thyroperoxidase antibodies and TRAb were neither significant nor correlated with CD20 + depletion (P = NS). CAS values before RTX were 4.7 ± 0.5 and decreased to 1.8 ± 0.8 at the end of follow-up (P

UR - http://www.scopus.com/inward/record.url?scp=33847727902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847727902&partnerID=8YFLogxK

U2 - 10.1530/eje.1.02325

DO - 10.1530/eje.1.02325

M3 - Article

C2 - 17218723

AN - SCOPUS:33847727902

VL - 156

SP - 33

EP - 40

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

SN - 0804-4643

IS - 1

ER -